8-K: Teva's Innovative Portfolio Drives Strong Q2 2025 Growth, Raises Full-Year EPS and Key Product Outlook

Teva Pharmaceutical Industries Ltd. reported its tenth consecutive quarter of year-over-year revenue growth in Q2 2025, fueled by its innovative product portfolio, leading to an increased 2025 revenue outlook for key innovative products and EPS.

Summary

• Revenues for Q2 2025 were $4.2 billion, flat in U.S. dollars and a decrease of 1% in local currency terms compared to Q2 2024, excluding Japan BV revenues.
• This marks the 10th consecutive quarter of year-over-year revenue growth.
• The innovative portfolio (AUSTEDO, AJOVY, UZEDY) collectively grew approximately 26% year-over-year in local currency in Q2 2025.
• AUSTEDO global revenues reached $498 million in Q2 2025, a 19% increase in local currency compared to Q2 2024, with U.S. revenues up 22%.
• AJOVY global revenues were $155 million in Q2 2025, a 31% increase in local currency compared to Q2 2024.
• UZEDY revenues accelerated to $54 million in Q2 2025, a 120% increase compared to Q2 2024.
• The 2025 revenue outlook for AUSTEDO was increased to $2,000 million $2,050 million, for AJOVY to $630 million $640 million, and for UZEDY to $190 million $200 million.
• Global generics performance showed a 2% decrease in local currency year-over-year, excluding Japan BV, with U.S. generics down 6%, Europe up 1%, and International Markets down 1%.
• Strong biosimilars performance was noted, with expectations for two new launches in the second half of 2025 and a target to double biosimilar revenues from 2024 to 2027.
• Teva Transformation programs are on track to deliver approximately $700 million of net savings by 2027, with approximately $70 million net savings expected in 2025 (or ~$140 million on a full-year run-rate basis).
• GAAP diluted EPS for Q2 2025 was $0.24, compared to a loss of $0.75 in Q2 2024.
• Non-GAAP diluted EPS for Q2 2025 was $0.66, an increase of 9% year-over-year.
• Cash flow generated from operating activities was $227 million in Q2 2025, up from $103 million in Q2 2024.
• Free cash flow was $476 million in Q2 2025, a 47% increase year-over-year.
• Total debt as of June 30, 2025, was $17,227 million, down from $17,783 million as of December 31, 2024.
• The 2025 Non-GAAP diluted EPS outlook was increased to $2.50 $2.65 (+$0.05 at the low-end), while other outlook components (total revenues, non-GAAP operating income, adjusted EBITDA, free cash flow) were reaffirmed.

Sentiment

Score: 8

Explanation: The filing indicates strong performance driven by the innovative portfolio, significant growth in key products, increased financial outlook for EPS and innovative product revenues, and substantial progress on strategic transformation and debt reduction. While generics face headwinds, the overall trajectory is positive and aligns with strategic goals.

Positives

• Achieved 10th consecutive quarter of year-over-year revenue growth.
• Innovative portfolio demonstrated strong growth, with AUSTEDO revenues up 19% in local currency, AJOVY up 31% in local currency, and UZEDY up 120% year-over-year.
• Increased 2025 revenue outlook for key innovative products: AUSTEDO to $2,000M-$2,050M, AJOVY to $630M-$640M, and UZEDY to $190M-$200M.
• Non-GAAP diluted EPS increased by 9% year-over-year to $0.66 in Q2 2025, and the 2025 outlook was raised.
• Free cash flow significantly increased by 47% year-over-year to $476 million in Q2 2025.
• GAAP operating income improved from a loss of $5 million in Q2 2024 to a profit of $455 million in Q2 2025.
• Non-GAAP operating margin increased to 27.1% in Q2 2025 from 25.3% in Q2 2024.
• Reduced total debt to $17,227 million from $17,783 million since December 31, 2024.
• Strong biosimilars performance, with two new launches expected in H2 2025 and a target to double biosimilar revenues by 2027.
• Transformation programs are on track to deliver approximately $700 million in net savings by 2027, with initial savings already being realized.
• Advanced innovative pipeline assets with anticipated U.S. NDA submission for olanzapine LAI and initiation of duvakitug UC and CD programs in Q4 2025.

Negatives

• Overall revenues were flat in U.S. dollars and decreased by 1% in local currency terms (excluding Japan BV revenues) compared to Q2 2024.
• International Markets segment revenues decreased by 17% (16% in local currency) primarily due to the divestment of the business venture in Japan.
• Generic products revenues in the U.S. decreased by 6% and in International Markets by 1% in local currency.
• COPAXONE revenues continued to decline across all segments (U.S. -23%, Europe -6% LC, International Markets -50%).
• Anda distribution business revenues decreased by 2% due to lower volumes.
• API sales to third parties decreased by 11% in both U.S. dollars and local currency terms.
• General and Administrative (G&A) expenses increased by 8% due to costs related to optimization activities.
• Legal settlements and loss contingencies increased to $166 million in Q2 2025 from $83 million in Q2 2024.

Risks

• Substantial dependence on generic products and intense competition from other pharmaceutical companies.
• Concentration of the customer base and commercial alliances among customers.
• Changes in regulatory policy that may result in additional costs and delays for generic medicines.
• Delays in launches of new generic products.
• Ability to develop and commercialize additional pharmaceutical products and achieve expected results from investments in the product pipeline.
• Competition for innovative medicines.
• Ability to successfully execute the 'Pivot to Growth' strategy, including expanding innovative and biosimilar medicines pipeline, profitably commercializing the portfolio, sustaining and focusing generics, and achieving expected cost savings from organizational transformation.
• Effectiveness of patents and other measures to protect intellectual property rights, including potential challenges to Orange Book patent listings in the U.S.
• Significant indebtedness may limit the ability to incur additional indebtedness, engage in additional transactions, or make new investments.
• Potential need to raise additional funds in the future, which may not be available on acceptable terms or at all.
• Impact of global economic conditions and other macroeconomic developments, and governmental/societal responses.
• Widespread outbreak of an illness or any other communicable disease, or any other public health crisis.
• Effectiveness of optimization efforts.
• Significant disruptions of information technology systems, including cybersecurity attacks and breaches of data security.
• Interruptions in the supply chain or problems with internal or third-party manufacturing.
• Challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism, such as the ongoing conflict between Russia and Ukraine and the state of war declared in Israel.
• Ability to attract, hire, integrate, and retain highly skilled personnel.
• Ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions.
• Prospects and opportunities for growth if assets or business units are sold and plants/facilities are closed or divested, as well as the ability to successfully and cost-effectively consummate such sales and divestitures, including the planned divestiture of the API business.
• Failure to comply with complex legal and regulatory environments.
• Effects of governmental and civil proceedings and litigation.
• Effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement, and coverage, including as a result of the 'One Big Beautiful Bill' (OBBBA) and U.S. Executive Orders issued in April and May 2025.
• Increased legal and regulatory action in connection with public concern over the abuse of opioid medications.
• Ability to timely make payments required under the nationwide opioids settlement agreement and provide generic Narcan.
• Scrutiny from competition and pricing authorities around the world, including compliance with the deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ).
• Potential liability for intellectual property right infringement and product liability claims.
• Failure to comply with complex Medicare, Medicaid, and other governmental programs reporting and payment obligations.
• Compliance with sanctions and trade control laws.
• Environmental risks and the impact of ESG issues.
• Impact of the state of war declared in Israel and military activity in the Middle East, including disruptions to operations and facilities located in Israel, impact of employees who are military reservists, and the war's effect on Israel's stability.
• Exposure to currency fluctuations and restrictions, as well as credit risks.
• Potential impairments of long-lived assets.
• Potential significant increases in tax liabilities and the effect on the overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in the business.
• Exposure to changes in international trade policies, including the imposition of tariffs.
• Impact of any future failure to establish and maintain effective internal control over financial reporting.

Future Outlook

Teva reaffirms its 2025 revenue, non-GAAP operating income, adjusted EBITDA, and free cash flow outlook, while increasing the outlook for key innovative products (AUSTEDO, AJOVY, UZEDY) and non-GAAP diluted EPS. The company is on track to achieve a 30% operating profit margin by 2027 as part of its 'Pivot to Growth' strategy, which includes accelerating innovative pipeline assets like olanzapine LAI and duvakitug, and doubling biosimilar revenues by 2027. Transformation programs are expected to generate approximately $700 million in net savings by 2027.

Management Comments

• "Teva's performance this quarter stands as a testament to the exceptional strength of our innovative portfolio, which remains the primary engine driving our revenue growth." Mr. Richard Francis, Teva's President and CEO.
• "Our key innovative products delivered a 26% increase in local currency, demonstrating their impact on our financial trajectory and value to patients." Mr. Richard Francis, Teva's President and CEO.
• "As we execute our Pivot to Growth strategy, our focus on innovation is unwavering, placing us firmly on track to achieve a 30% operating profit margin by 2027." Mr. Richard Francis, Teva's President and CEO.
• "The rapid advancement of our transformation programs is already unlocking ~$140 million in annual run-rate savings in 2025, a critical milestone toward our overall ~$700 million net savings target by 2027." Mr. Richard Francis, Teva's President and CEO.
• "While our relentless commitment to advancing our innovative portfolio now truly sets Teva apart, our generics business continues to provide a stable foundation despite headwinds." Mr. Richard Francis, Teva's President and CEO.
• "The momentum behind our OTC products and biosimilars, together with our current portfolio and pipeline, reinforce our ambition to double biosimilars revenues by 2027." Mr. Richard Francis, Teva's President and CEO.

Industry Context

Teva's Q2 2025 results reflect a broader trend in the pharmaceutical industry where growth is increasingly driven by innovative and specialty products, alongside the emerging biosimilar market, while traditional generics face persistent pricing pressures and increased competition. The company's 'Pivot to Growth' strategy, emphasizing higher-value assets and operational efficiency, aligns with this industry shift, aiming to offset declines in legacy products like COPAXONE and certain generic segments. The strong performance of AUSTEDO, AJOVY, and UZEDY, coupled with aggressive biosimilar expansion plans, positions Teva to capitalize on these growth areas. The mention of the 'One Big Beautiful Bill' (OBBBA) and U.S. Executive Orders highlights the increasing regulatory scrutiny and pressure on drug pricing in the U.S., a significant industry challenge that could impact future revenues for key innovative products.

Comparison to Industry Standards

• AJOVY's exit market share in the U.S. subcutaneous injectable anti-CGRP class increased to 31.0% in Q2 2025 from 28.6% in Q2 2024, indicating strong competitive positioning against rivals such as Amgen's Aimovig, Eli Lilly's Emgality, and Lundbeck's Vyepti.
• UZEDY's 120% year-over-year growth demonstrates rapid market penetration for a relatively new product in the long-acting injectable antipsychotic market, competing with established products like Janssen's Invega Sustenna/Trinza.
• The launch of EPYSQLI (eculizumab-aagh), a biosimilar to Soliris (eculizumab), positions Teva in the high-value biosimilar market, competing with other biosimilar developers and the originator product from Alexion Pharmaceuticals.
• Teva's ambition to double biosimilar revenues from 2024 to 2027 is an aggressive growth target, reflecting a strategic focus on this high-growth segment, a common strategy among large generic pharmaceutical companies seeking higher-margin opportunities.
• The decline in the overall generics business, particularly in the U.S. and International Markets, is consistent with broader industry trends of increased competition and pricing pressure on off-patent drugs, as seen with lenalidomide capsules (generic Revlimid) and liraglutide injection (generic Victoza).

Legal Proceedings

• The Centers for Medicare and Medicaid Services (CMS) selected AUSTEDO and AUSTEDO XR for price-setting discussions, with revised prices expected to become effective on January 1, 2027. The extent of price change is uncertain.
• Legal settlements and loss contingencies of $166 million in Q2 2025, mainly due to an update to the estimated settlement provision for opioid cases ($47 million) and an update to the estimated provision for generic drug antitrust litigation ($55 million).
• The company faces risks related to governmental and civil proceedings and litigation.
• There is increased legal and regulatory action in connection with public concern over the abuse of opioid medications.
• The company must timely make payments and provide its generic version of Narcan (naloxone hydrochloride nasal spray) as required under its nationwide opioids settlement agreement.
• The company is subject to scrutiny from competition and pricing authorities around the world, including compliance with its deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ).
• Potential liability exists for intellectual property right infringement and product liability claims.
• The company must comply with complex Medicare, Medicaid, and other governmental programs reporting and payment obligations.
• Compliance with sanctions and trade control laws is required.

Stakeholder Impact

• Shareholders are positively impacted by the increased EPS outlook, strong growth in innovative products, debt reduction, and progress on strategic transformation, indicating potential for long-term value creation.
• Patients benefit from the continued focus on addressing medical needs through the innovative portfolio (AUSTEDO, AJOVY, UZEDY) and the expansion of biosimilars, offering more treatment options.
• Employees may be impacted by 'optimization activities' and 'headcount reduction' as part of Teva's Transformation programs.
• Customers, including independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices, continue to receive generic and innovative medicines, including newly launched biosimilars, through Teva's distribution network.
• Creditors are positively impacted by the company's debt reduction and refinancing efforts, which enhance financial stability and reduce leverage.

Next Steps

• File the U.S. NDA for olanzapine LAI in Q4 2025.
• Target full enrollment for DARIs (Dual-action Asthma Rescue Inhaler) Phase 3 trial at the end of 2025.
• Announce the start of the Phase 3 Crohns disease and ulcerative colitis programs for duvakitug in Q4 2025.
• Continue efforts to sell the active pharmaceutical ingredient (API) business.
• Expect two new biosimilar launches in the second half of 2025.
• Continue executing on the 'Pivot to Growth' strategy, focusing on accelerating growth, aligning capital allocation, reinforcing commitment to patients, and optimizing organization and operations.
• Host a conference call and live webcast on July 30, 2025, to discuss the second quarter 2025 financial results and overall business environment.

Key Dates

Recommendation

The filing demonstrates a clear positive inflection point for Teva, driven by robust growth in its high-margin innovative product portfolio (AUSTEDO, AJOVY, UZEDY), which significantly exceeded expectations and led to an upward revision of their 2025 revenue outlook. The substantial increase in Non-GAAP diluted EPS outlook and free cash flow generation indicates improving profitability and financial health. The company's 'Pivot to Growth' strategy is showing tangible results, with significant progress on cost savings and debt reduction. While the generics business faces expected headwinds, the strong performance of innovative and biosimilar segments, coupled with strategic divestitures (Japan BV, planned API sale) to streamline the portfolio, positions Teva for sustained growth and margin expansion towards its 2027 operating profit target. The market may not fully price in the accelerating momentum of the innovative pipeline and the successful execution of the transformation programs. The risks, while present, are well-known and being actively managed, and the positive operational and financial trends outweigh the challenges.

Keywords

Pharmaceutical, Innovative Medicines, Biosimilars, Generics, Teva, AUSTEDO, AJOVY, UZEDY, Drug Development, Financial Results, Q2 2025, Earnings, Healthcare, Biotech, API, Debt Reduction, Transformation Strategy